Squarepoint’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Squarepoint’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-15,400	Closed	-$27K	–	2221
2016 Q4	$27K	Buy	+15,400	New	+$36.2K	﹤0.01%	1721
2016 Q3	–	Sell	-17,930	Closed	-$77K	–	1503
2016 Q2	$77K	Buy	+17,930	New	+$81.1K	﹤0.01%	995
2016 Q1	–	Sell	-16,640	Closed	-$287K	–	1702
2015 Q4	$287K	Buy	+16,640	New	+$397K	0.03%	816

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

GLG LLC New York $1.39B AUM 24.01% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OWIM

Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return

Squarepoint's OREX Position: Q1 2017 in Review

Squarepoint sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2017, closing a stake of 15,400 shares — an estimated $27K sold.

Squarepoint first reported a position in OREX in Q4 2015 and held it in 3 quarters. The position peaked at $287K in Q4 2015. 52 funds tracked by Wall St. Rank hold OREX as of Q1 2017.

Squarepoint reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
Squarepoint sold 15,400 Orexigen Therapeutics, Inc. shares in Q1 2017, an estimated $27K.
Squarepoint first reported a position in Orexigen Therapeutics, Inc. in Q4 2015 and held it in 3 quarters.
Squarepoint's Orexigen Therapeutics, Inc. position peaked at $287K in Q4 2015.
52 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2017.

Based on Squarepoint's 13F filing for Q1 2017, filed 15 May 2017.